Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GZR18 in Obese Subjects With Moderate to Severe Obstructive Sleep Apnea
NCT07493057Phase 3Not yet recruiting
- Sponsor
- Gan & Lee Pharmaceuticals
- Start
- Apr 2026
- Primary completion
- Nov 2027
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of bofanglutide in obstructive sleep apnea (OSA), sponsored by Gan & Lee Pharmaceuticals. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
bofanglutide
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT07493057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07493057.